跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

Y0000576

Lorazepam for system suitability

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
(±)-Lorazepam, 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one
经验公式（希尔记法）:
C15H10Cl2N2O2
CAS号:
846-49-1
分子量:
321.16
MDL编号:
MFCD00063406
UNSPSC代码:
41116107
PubChem化学物质编号:
329831029
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

lorazepam

制造商/商品名称

EDQM

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

InChI key

DIWRORZWFLOCLC-UHFFFAOYSA-N

基因信息

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Lorazepam for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

1370327

Lorazepam Related Compound A, United States Pharmacopeia (USP) Reference Standard

L0750500

Lorazepam, European Pharmacopoeia (EP) Reference Standard

1370305

Lorazepam, United States Pharmacopeia (USP) Reference Standard

1370338

2-氨基-2′,5-二氯苯甲酮, United States Pharmacopeia (USP) Reference Standard

Y0000718

Lorazepam impurity D, European Pharmacopoeia (EP) Reference Standard

1370349

Lorazepam Related Compound C, United States Pharmacopeia (USP) Reference Standard

1370350

Lorazepam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1370360

Lorazepam Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP434

劳拉西泮标准液, British Pharmacopoeia (BP) Reference Standard

BP376

6-氯-4-(2-氯苯基)喹唑啉-2-甲醛, British Pharmacopoeia (BP) Reference Standard

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361d

危险分类

Repr. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jason T McMullan et al.
Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors, 17(1), 1-7 (2012-11-15)
The choice of the optimal benzodiazepine to treat prehospital status epilepticus is unclear. Lorazepam is preferred in the emergency department, but concerns about nonrefrigerated storage limits emergency medical services (EMS) use. Midazolam is increasingly popular, but its heat stability is
Olugbenga A Akingbola et al.
American journal of critical care : an official publication, American Association of Critical-Care Nurses, 21(6), 456-459 (2012-11-03)
A 6-year-old girl displayed symptoms of serotonin syndrome after accidental ingestion of Vyvanse (lisdexamfetamine dimesylate). Dexmedetomidine was administered because of persistent neuromuscular hyperactivity and severe agitation despite initial therapy with benzodiazepines. Some children show a paradoxical reaction to benzodiazepines, and
Thomas P Bravo et al.
The neurologist, 19(1), 30-33 (2012-12-28)
Psychogenic nonepileptic seizures (PNES) are commonly encountered problem in neurological practice and usually are accompanied by other psychiatric comorbidities. Despite its prevalence and profound impact on patients and families, there have been few trials addressing treatment. Cognitive behavioral therapy may
Preemptive use of palliative sedation and amyotrophic lateral sclerosis.
Judith A C Rietjens et al.
Journal of pain and symptom management, 44(3), e5-e7 (2012-09-04)
Natalie L Jacobowski et al.
Journal of psychiatric practice, 19(1), 15-28 (2013-01-22)
Delirious mania is a severe but under-recognized neuropsychiatric syndrome characterized by the rapid onset of delirium, mania, and psychosis, not associated with a prior toxicity, physical illness, or mental disorder. Catatonia is often a prominent feature of the syndrome. While
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门